A PHASE III, OPEN-LABEL, MULTICENTER,TWO-ARM, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF COBIMETINIB PLUS ATEZOLIZUMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED BRAFV600 WILD-TYPE MELANOMA
Study of efficacy and safety of cobimetinib plus atezolizumab in patients with untreated melanoma
Sponsor: Genentech
Enrolling: Male and Female Patients
IRB Number: AAAR4467
U.S. Govt. ID: NCT03273153
Contact: Richard Carvajal MD: 646-317-6041 / rdc2150@cumc.columbia.edu
Additional Study Information: The purpose of this study is to compare the efficacy and safety of cobimetinib plus atezolizumab with the efficacy and safety of pembrolizumab in patients with a type of skin cancer called melanoma that has spread to other parts of the body (metastatic), cannot be removed by surgery (unresectable), and have not received any prior treatment.
This study is closed
Investigator
Richard Carvajal, MD
Do You Qualify?
Do you have a type of skin cancer called melanoma? Yes No
Has your skin cancer spread to other parts of your body? Yes No
Have you received treatment before? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Richard Carvajal MD
rdc2150@cumc.columbia.edu
646-317-6041
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE